Lucid Diagnostics Inc. (LUCD) stock
LUCDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3078% above fair value
$0.45+0.03 (+7.88%)
Close on Nov 13, 2026Market cap $91.28MP/E –Yield –
Lucid Diagnostics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Lucid Diagnostics's ebitda for the twelve months ending Sep 30, 2026 was -$50.32M. For fiscal 2025 it was -$48.77M. The highest annual figure on record is -$27.42M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$48.77M | – |
| FY2024 | Dec 31, 2024 | -$44.89M | – |
| FY2023 | Dec 31, 2023 | -$45.98M | – |
| FY2022 | Dec 31, 2022 | -$54.32M | – |
| FY2021 | Dec 31, 2021 | -$27.42M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$12.05M | – |
| Q2 FY2026 | Jun 30, 2026 | -$12.58M | – |
| Q1 FY2026 | Mar 31, 2026 | -$11.89M | – |
| Q4 FY2025 | Dec 31, 2025 | -$13.80M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.54M | – |
| Q2 FY2025 | Jun 30, 2025 | -$11.16M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.27M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.15M | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.48M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.96M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.29M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.82M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.50M | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.95M | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.71M | – |
| Q4 FY2022 | Dec 31, 2022 | -$14.36M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.78M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.92M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.25M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.24M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.51M | – |
See a number that looks wrong?